Sponsored Links
| Furiex Receives FDA Fast Track Designation Of MuDelta For The Treatment Of Diarrhea-Predominant Irritable Bowel Syndrome |
 |
 |
 |
| Medical News - Irritable-Bowel Syndrome | |
|
Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) announced that its novel diarrhea-predominant irritable bowel syndrome treatment called MuDelta, now in Phase II clinical trials, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA)... Read more: Irritable-Bowel Syndrome News From Medical News Today
|